Corporate Members

Diamond Elite





Latest News

Boehringer Ingelheim Patient Assistance Program

Boehringer Ingelheim is on a mission to improve lives around the world. We do this by developing innovative medicines and helping patients gain access to them – wherever they may be – and by supporting innovative programs that help ensure the health of individuals and communities in this and future generations.

FDA Approves Mogamulizumab-kpkc for Two Rare Types of Non-Hodgkin Lymphoma

U.S. Food and Drug Administration approved mogamulizumab-kpkc (Poteligeo) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy. This approval provides a new treatment option for patients with mycosis fungoides and is the first FDA approval of a drug specifically...

Florida Cancer Specialists & Research Institute Welcomes Dr. Simon Abi Aad

New Medical Oncologist Joins in Naples Naples, FL – August 6th, 2018. . . Florida Cancer Specialists & Research Institute (FCS), the largest community oncology/hematology practice in the state, is pleased to announce that medical oncologist Simon Abi Aad, MD, has joined the statewide practice and will be practicing at the Naples Napa Ridge office, located at 6360 Pine Ridge Road,...

FDA Approves Iobenguane I-131 for Rare Adrenal Gland Tumors

On July 30, the U.S. Food and Drug Administration (FDA) approved iobenguane I-131 (Azedra) injection for adult and pediatric patients (12 years and older) with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy. “Many patients with these ultra-rare cancers can be treated with surgery or local therapies, but there...

Shionogi & Co Ltd’s treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease approved by FDA

On July 31, 2018, the Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. Approval was based on two randomized, double-blind, placebo-controlled trials (L-PLUS 1 and L-PLUS 2, NCT02389621) involving 312 patients with chronic liver disease and...

Who’s Online

Profile picture of FLASCO